Patients’ demographics and clinical characteristics
| IJD n=5207 (71%) | CTD n=1320 (18%) | Vasculitis n=686 (9.4%) | OIRMD n=123 (1.7%) | All patients n=7336 | ||
| Age, years | Mean (SD) | 58.2 (15) | 54.5 (15.9) | 67.7 (15.1) | 53.3 (13.7) | 58.3 (15.5) |
| Range | 18–96 | 18–90 | 19–95 | 18–87 | 18–96 | |
| Sex | Female | 3356 (64.5) | 1153 (87.3) | 407 (59.3) | 67 (54.5) | 4983 (67.9) |
| Male | 1851 (35.5) | 167 (12.7) | 279 (40.7) | 56 (45.5) | 2353 (32.1) | |
| Country | Portugal | 1892 (36.3) | 341 (25.8) | 21 (3.1) | 1 (0.8) | 2255 (30.7) |
| France | 1095 (21) | 489 (37) | 326 (47.5) | 67 (54.5) | 1977 (26.9) | |
| Italy | 716 (13.8) | 219 (16.6) | 136 (19.8) | 28 (22.8) | 1099 (15) | |
| Slovakia | 348 (6.7) | 45 (3.4) | 36 (5.2) | 0 | 429 (5.8) | |
| Latvia | 284 (5.5) | 47 (3.6) | 20 (2.9) | 0 | 351 (4.8) | |
| Other countries* | 872 (16.7) | 179 (13.6) | 147 (21.4) | 27 (22) | 1225 (16.7) | |
| Primary I-RMD diagnosis | Rheumatoid arthritis | 2647 (50.1) | NA | NA | NA | 2647 (36.1) |
| Axial spondyloarthritis | 1184 (22.7) | NA | NA | NA | 1184 (16.1) | |
| Psoriatic arthritis | 892 (17.1) | NA | NA | NA | 892 (12.2) | |
| Other peripheral spondyloarthritis (including reactive arthritis) | 178 (3.4) | NA | NA | NA | 178 (2.4) | |
| Non-systemic juvenile idiopathic arthritis | 88 (1.7) | NA | NA | NA | 88 (1.2) | |
| Systemic juvenile idiopathic arthritis | 14 (<1) | NA | NA | NA | 14 (<1) | |
| Gout or other crystal arthritis | 100 (1.9) | NA | NA | NA | 100 (1.4) | |
| Other inflammatory arthritis | 104 (2) | NA | NA | NA | 104 (1.4) | |
| Systemic lupus erythematosus | NA | 546 (41.4) | NA | NA | 546 (7.4) | |
| Primary antiphospholipid syndrome | NA | 33 (2.5) | NA | NA | 33 (<1) | |
| Sjogren’s syndrome | NA | 294 (22.3) | NA | NA | 294 (4) | |
| Systemic sclerosis | NA | 245 (18.6) | NA | NA | 245 (3.3) | |
| Idiopathic inflammatory myopathy | NA | 86 (6.5) | NA | NA | 86 (1.2) | |
| Mixed connective tissue disease | NA | 44 (3.3) | NA | NA | 44 (<1) | |
| Undifferentiated connective tissue disease | NA | 72 (5.5) | NA | NA | 72 (1) | |
| Large vessel vasculitis—Takayasu arteritis | NA | NA | 18 (2.6) | NA | 18 (<1) | |
| Large vessel vasculitis—giant cell arteritis | NA | NA | 157 (22.9) | NA | 157 (2.1) | |
| Polymyalgia rheumatica | NA | NA | 270 (39.4) | NA | 270 (3.7) | |
| Medium vessel vasculitis—polyarteritis nodosa, Kawasaki disease | NA | NA | 14 (2) | NA | 14 (<1) | |
| ANCA-associated vasculitis—MPA, GPA, EGPA | NA | NA | 139 (20.3) | NA | 139 (1.9) | |
| Immune complex small vessel vasculitis | NA | NA | 9 (1.3) | NA | 9 (<1) | |
| Bechet’s disease | NA | NA | 50 (7.3) | NA | 50 (<1) | |
| Other vasculitis | NA | NA | 29 (4.2) | NA | 29 (<1) | |
| Monogenic autoinflammatory syndrome | NA | NA | NA | 17 (13.8) | 17 (<1) | |
| Non-monogenic autoinflammatory syndrome | NA | NA | NA | 15 (12.2) | 15 (<1) | |
| IgG4-related disease | NA | NA | NA | 16 (13) | 16 (<1) | |
| Sarcoidosis | NA | NA | NA | 63 (51.2) | 63 (<1) | |
| Relapsing polychondritis | NA | NA | NA | 9 (7.3) | 9 (<1) | |
| Chronic recurrent multifocal osteomyelitis | NA | NA | NA | 3 (2.4) | 3 (<1) |
*Other countries include Albania, Australia, Austria, Belgium, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Ireland, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Republic of Moldova, Romania, Russian Federation, Slovenia, Spain, Switzerland, Turkey, Ukraine, USA and UK.
ANCA, antineutrophil cytoplasmic antibody; CTD, connective tissue disease; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; IJD, inflammatory joint disease; I-RMD, inflammatory rheumatic and musculoskeletal disease; MPA, microscopic polyangiitis; NA, not applicable; OIRMD, other inflammatory rheumatic and musculoskeletal disease.